Aurobindo Pharma has received a VAI (Voluntary Action Indicated) classification from the US Food and Drug Administration for its Unit-V of Apitoria Pharma following a recent regulatory inspection. The development represents a routine regulatory outcome that requires the company to address identified observations, with the inspection now officially closed.

USFDA Inspection and Classification Details

The regulatory inspection was conducted by the USFDA from December 1 to 12, 2025, spanning a comprehensive 12-day period at the API manufacturing facility located in Industrial Development Area, Chemical Zone, Pashamylaram Village, Patancheru Mandal, Sangareddy District, Telangana. Following the completion of the inspection, the agency issued Form 483, which contained three specific observations.

Establishment Inspection Report Received

The unit has now received an Establishment Inspection Report (EIR) from the USFDA, officially classifying the facility as VAI. The company has confirmed that this inspection is now closed, marking the completion of the regulatory review process for this particular inspection cycle.

Understanding VAI Classification

The VAI classification indicates that the USFDA has identified objectionable conditions or practices during the inspection that warrant correction. This classification falls in the middle range of regulatory outcomes, suggesting that while issues were identified, they do not meet the threshold for more severe regulatory actions such as Official Action Indicated (OAI) status.

Regulatory Compliance and Disclosure

Aurobindo Pharma has disclosed this development under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, demonstrating compliance with mandatory disclosure requirements. The VAI classification allows the facility to continue operations while maintaining regulatory compliance standards.

Apitoria Pharma Private Limited operates as a wholly owned subsidiary of Aurobindo Pharma Limited, specializing in API manufacturing. The facility's ability to continue operations under the VAI classification ensures business continuity while the company addresses the regulatory observations.

Aurobindo Pharma has received a Form 483 from the US Food and Drug Administration containing 9 observations related to its Eugia Pharma Unit-II facility. The regulatory communication represents a formal notice of deficiencies identified during an FDA inspection of the manufacturing facility from November 03 to November 14, 2025.

FDA Inspection Details

The US FDA inspected Unit-II of Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma, situated at RIICO Industrial Area, Phase-III, Bhiwadi, Rajasthan. Following the inspection completion, the FDA issued Form 483 with 9 observations and subsequently classified the facility as 'Official Action Indicated'.

Company Response and Business Impact

Aurobindo Pharma has informed stock exchanges about the FDA classification under SEBI Regulation 30. The company stated that it does not foresee any impact on business operations at this point in time. The pharmaceutical manufacturer emphasized its commitment to maintaining the highest quality manufacturing standards across all global facilities.

Regulatory Implications

Form 483 represents the FDA's official documentation of conditions or practices that may violate food, drug, or cosmetic regulations. The 'Official Action Indicated' designation suggests that the observations require formal response and corrective action from the pharmaceutical manufacturer to maintain compliance with FDA standards.